Scientists have discovered a protein that plays a central role in promoting immunity to viruses and cancer, opening the door to new therapies.
Experiments in mice and human cells have shown that the protein promotes the proliferation of cytotoxic T cells, which kill cancer cells and cells infected with viruses. The discovery was unexpected because the new protein had no known function and doesn’t resemble any other protein.
Researchers from Imperial College London who led the study are now developing a gene therapy designed to boost the infection-fighting cells, and hope to begin human trials in three years.
The study also involved researchers at Queen Mary University of London, ETH Zurich and Harvard Medical School. Their discovery, which has been six years in the making, is reported today in the journal Science.
Cytotoxic T cells are an important component of the immune system, but when faced with serious infections or advanced cancer, they are often unable to proliferate in large enough quantities to fight the disease.
By screening mice with genetic mutations, the Imperial team discovered a strain of mice that produced 10 times as many cytotoxic T cells when infected with a virus compared with normal mice. These mice suppressed the infection more effectively, and were more resistant to cancer. They also produced more of a second type of T cells, memory cells, enabling them to recognise infections they have encountered previously and launch a rapid response.
The mice with enhanced immunity produced high levels of a hitherto unknown protein, which the researchers named lymphocyte expansion molecule, or LEM. They went on to show that LEM modulates the proliferation of human T cells as well as in mice.
The researchers now aim to develop a gene therapy designed to improve immunity by boosting the production of LEM. With the support of Imperial Innovations, the technology commercialisation company for the College, the researchers have filed two patents. A company called ImmunarT has been formed with the aim of commercialising the technology.
Professor Philip Ashton-Rickardt from the Section of Immunobiology in the Department of Medicine at Imperial, who led the study, said: “Cancer cells have ways to suppress T cell activity, helping them to escape the immune system. Genetically engineering T cells to augment their ability to fight cancer has been a goal for some time and techniques for modifying them already exist. By introducing an active version of the LEM gene into the T cells of cancer patients, we hope we can provide a robust treatment for patients.
“Next we will test the therapy in mice, make sure it is safe and see if it can be combined with other therapies. If all goes well, we hope to be ready to carry out human trials in about three years.”
The Latest on: Cytotoxic T cell
[google_news title=”” keyword=”Cytotoxic T cell” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cytotoxic T cell
- Study finds diet-derived trans-vaccenic acid boosts anti-tumor immunityon November 28, 2023 at 2:10 am
Overall, the study findings showed that dietary trans-vaccenic acid increases effector cytotoxic T lymphocyte activity and anti-tumor immunity in the in vivo settings.
- Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitison November 27, 2023 at 9:44 am
Researchers from Skoltech contributed to a large study made by colleagues from Pirogov Russian National Research Medical University, Shemyakin-Ovchinnikov Institute of bioorganic chemistry and other ...
- Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapieson November 27, 2023 at 8:00 am
Myristoylation in SenescenceData published today in Nature Cell Biology by Myricx collaborators at the MRC-LMS (Laboratory of Medical Sciences) led by Prof. Jesús Gil have uncovered the central role ...
- ‘Time bomb’ cancer treatment could blow the ‘doors’ off tumour cells in major scientific breakthrough, experts sayon November 23, 2023 at 7:23 am
SCIENTISTS have discovered a way to blow the “doors” off cancer cells for the first time, a study shows. The new method triggers a “time bomb” in tumours that could open them up to new treatment, ...
- Pathogen-Sensing Plasmacytoid Dendritic Cells Stimulate Cytotoxic T-Cell Function in the Atherosclerotic Plaque Through Interferon-αon November 20, 2023 at 4:00 pm
IFN-α has also emerged as a biomarker in patients with chronic autoimmune syndromes, such as systemic lupus erythematosus, and IFN-α–mediated hyperstimulation of cytotoxic T-cell function may ...
- New lipidic peptide IK14004 shows promise in treating cancer and reducing autoimmune complicationson November 15, 2023 at 6:07 am
A recent study published in Nature’s Scientific Reports described a lipidic peptide, named IK14004, which fosters the growth of immunosuppressive T regulatory (Treg) cells and separates interleukin-2 ...
- Major cancer breakthrough as scientists discover 'kill switch' that destroys cellson November 13, 2023 at 6:40 am
Researchers believe they have discovered a protein on a receptor that can 'program' cancer cells to die, in a potential breakthrough for treating the disease.
- A microRNA Family Drives the T Cell Response in Canceron November 10, 2023 at 4:00 pm
To avoid an overreactive response that harms healthy cells, cytotoxic T lymphocytes express inhibitory surface receptors, or immune checkpoint molecules. Tumors can avoid attack by binding to these ...
- T-Cell Discovery Has Potential for Engineering Custom Immune Responseson October 29, 2023 at 5:00 pm
Until now, understanding how a T cell forms into a specific role, for example a cell-killing (cytotoxic) T cell or memory T cell, has eluded us. In a just-published paper in Cell Reports, ISB ...
via Bing News